Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 14/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.58 |
| ▸ | WNT1 | P04628 | 8/20 | 0.58 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31380017 | 1.00 | MKNK1 (0.64) | MKNK1GSK3BDYRK1AWNT1CCNE2 | |
| SCHEMBL25645546 | 0.81 | MKNK1 (0.66) | MKNK1GSK3BDYRK1AWNT1CCNE2 | |
| SCHEMBL31472544 | 0.81 | MKNK1 (0.66) | MKNK1GSK3BDYRK1AWNT1CCNE2 | |
| SCHEMBL30481235 | 0.81 | MKNK1 (0.66) | MKNK1GSK3BDYRK1AWNT1CCNE2 | |
| SCHEMBL25854733 | 0.80 | MKNK1 (0.64) | MKNK1GSK3BDYRK1AWNT1CCNE2 | |
| SCHEMBL25612167 | 0.80 | MKNK1 (0.64) | MKNK1GSK3BDYRK1AWNT1CCNE2 | |
| SCHEMBL25611765 | 0.80 | DYRK1A (0.74) | MKNK1GSK3BDYRK1AWNT1 | |
| SCHEMBL25610637 | 0.80 | MKNK1 (0.63) | MKNK1GSK3BDYRK1AWNT1CCNE2 | |
| SCHEMBL31271579 | 0.80 | MKNK1 (0.63) | MKNK1GSK3BDYRK1AWNT1CCNE2 | |
| SCHEMBL30481248 | 0.79 | MKNK1 (0.62) | MKNK1GSK3BDYRK1AWNT1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |